TAK-960 hydrochloride is primarily used in research and development within the field of oncology. It functions as a potent and selective inhibitor of polo-like kinase 1 (PLK1), an enzyme that plays a critical role in cell division and mitosis. By inhibiting PLK1, it disrupts the proliferation of cancer cells, making it a potential candidate for cancer therapy. Its application is particularly significant in studying various types of cancers, including solid tumors and hematological malignancies, to understand its efficacy and mechanism of action. Preclinical studies have shown promising results in reducing tumor growth, which supports its potential use in targeted cancer treatments. However, its clinical application is still under investigation, and further studies are required to assess its safety and effectiveness in humans.